Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Missing Link Points to New Diabetes Target

Scientists suggest that a protein known as thioredoxin-interacting protein (TXNIP) could represent a new target for diabetes and potentially other human diseases such as Wolfram syndrome that are associated with endoplasmic reticulum stress (ER stress). The re

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Scientists suggest that a protein known as thioredoxin-interacting protein (TXNIP) could represent a new target for diabetes and potentially other human diseases such as Wolfram syndrome that are associated with endoplasmic reticulum stress (ER stress). The researchers, headed by a University of Massachusetts (UMass) Medical School team, have found that TXNIP effectively triggers cell inflammatory responses as a result of ER stress caused by chronic high glucose levels, which leads directly to the death of insulin-producing β cells in the pancreas.

Recent evidence suggests that crosstalk between inflammation and ER stress plays a role in the loss of β cells during the progression of type 1 and type 2 diabetes and Wolfram syndrome, a genetic form of diabetes and neurodegeneration. ER stress caused by cellular disturbances is associated with a buildup of unfolded proteins in the endoplasmic reticulum, which can lead to cell death if the cells’ unfolded protein response (UPR) repair mechanism can’t correct the problem. However, a key molecule that links ER stress to inflammation hasn’t yet been identified.

To try and find this link the UMass researchers built on experimental results indicating that TXNIP plays a role in β cell death in diabetes. They looked at mouse pancreatic tissue to see whether the protein was actually produced by β cells and determine its signalling pattern. They initially confirmed that TXNIP was highly expressed in insulin-producing β cells, and that subjecting the cells to chemical ER stress inducers or high levels of glucose, which also causes ER stress, triggered even higher levels of TXNIP mRNA expression. Importantly, TXNIP mRNA expression was increased in human primary islets following treatment with chemical ER stress inducers.

Subsequent analysis of TXNIP-related pathways showed that expression of the protein was induced by ER stress as part of the resulting UPR, leading to the production of interleukin 1β and subsequently β cell death. The results indicated that TXNIP production is induced by ER stress through the PERK and IRE1 pathways, leading to IL-1β mRNA transcription, activation of IL-1β production by the NLRP3 inflammasome, and thus eventually ER stress-mediated β cell death.

In essence, the team suggests, a range of stress-signalling pathways appear to converge at TXNIP, leading to inflammasome activation and IL-1β production, which has catastrophic effects on the β cell. “Our findings unexpectedly revealed that the UPR regulates IL-1β production through TXNIP,” write Fumihiko Urano, M.D., and colleagues in Cell Metabolism. “We propose that during diabetes, TXNIP expression is induced through the UPR and leads to β cell inflammation and apoptosis… Our data combined with recent findings indicate that there exists a tight link between ER stress, oxidative stress, glucose toxicity, and inflammation, suggesting that a therapeutic strategy that aims to target the common molecular processes that are altered in stressed β cells might be effective.”

Dr. Urano, et al describe their findings in a paper titled “Thioredoxin-Interacting Protein Mediates ER Stress-Induced β Cell Death through Initiation of the Inflammasome.”

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Related questions

01How stable is the antibody?

A crucial question often addressed during preclinical development focuses on the in vivo stability of therapeutic antibodies. Increasing the half-life of a therapeutic antibody has several benefits ranging from higher treatment efficacy to increased advantages for the patients who will have a fewer number of therapy sessions and a reduced cost. Given these compelling benefits, following the identification of therapeutic antibodies with the desired specificity, developers usually subject them to a refinement step to increase their stability. This process is often hindered by the lack of reliable experimental tools to predict the half-life of antibodies in patients. The major hurdle of using mouse models to predict antibody stability in the serum lies in the way immunoglobulin proteins are processed by the organism. In mammals, most proteins circulating in the serum undergo constant uptake by endothelial cells and are routed through the endosomes to the lysosomal compartment for degradation. In the endosomes, immunoglobulin G (IgG) proteins are recognized and bound by a transmembrane protein, called the neonatal Fc receptor (FcRn), which mediates their recycling to the plasma membrane and subsequent release back into the serum. As a result, the half-life of IgGs are significantly extended by this mechanism. Since most therapeutic antibodies belong to the IgG class, this recycling system is very relevant for their relative stability in the body. Remarkably, the relative affinity between IgGs and FcRn is extremely disparate between different species, with the mouse receptor showing a much higher affinity than its human counterpart.

Source: www.genengnews.com ↗
02Undruggable or unscreenable?

Another obstacle to discovering new PPI inhibitors is the lack of libraries designed to hunt for them, points out Philippe Roche, PhD, senior scientist at the Integrative Structural and Chemical Biology team at the Cancer Research Center of Marseilles, France. “If you screen PPIs using libraries that were designed for kinases or GPCRs, that’s why you don’t get a lot of good results,” he says. To that end, his group began assembling a library focused on orthosteric inhibitors of PPIs. The result was 2P2Idb, a hand-curated, structural database cataloguing orthosteric inhibitors of PPIs for which the interface had been 3D characterized. From analyzing these known PPI inhibitors, and what structures they had in common, Roche and his colleagues developed a model to predict whether compounds would likely inhibit PPIs. Using this method, 2P2Idb creates an enriched screening library that dramatically increases the hit rate compared to standard libraries. Having proven their success with a small library of 1600 compounds, they are in the process of expanding the library to 10,000 compounds. Once that’s published, “the idea is to make this library available to labs around the world,” Roche says. “We will provide the library free of charge for people to be able to screen PPI targets.”

Source: www.genengnews.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →